Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited)
External resources NEJM Phase 2 Trial: Triple Hormone Receptor Agonist Retatrutide for Obesity PMC Review: Retatrutide - A Game Changer in Obesity Pharmacotherapy ClinicalTrials.gov: Retatrutide TRIUMPH Clinical Trial Registry Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol builders, dosing calculators, and a community of thousands who have navigated these exact questions
While shortages and side effects are common causes of non-adherence, study authors also noted the importance of understanding obesity care management program needs. Employers must also grapple with the cost of GLP-1s
Schellack, G., Harirari, P., & Schellack, N
